Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Piedmont Healthcare
- Target Recruit Count
- 50
- Registration Number
- NCT03929718
- Locations
- 🇺🇸
Piedmont Heart Institute, Atlanta, Georgia, United States
Venetoclax and Lintuzumab-Ac225 in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT03867682
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸University of Louisville, Louisville, Kentucky, United States
Spironolactone Versus Prednisolone in DMD
- Conditions
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 2
- Registration Number
- NCT03777319
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 68
- Registration Number
- NCT03682497
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Spironolactone Versus Indapamide in Obese and Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT03626506
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT03597035
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 120
- Registration Number
- NCT03593317
- Locations
- 🇫🇷
Hôpital Cardiologique Louis Pradel, Bron, France
🇫🇷CHU Amiens Picardie, Amiens, France
🇫🇷Hôpital Gabriel Montpied, Clermont-ferrand, France
Hypoglycemia and Autonomic Nervous System Function-B
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT03429946
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Spironolactone Therapy in Chronic Stable Right HF Trial
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 15
- Registration Number
- NCT03344159
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 158
- Registration Number
- NCT03334682
- Locations
- 🇫🇷
CH La Rochelle, La Rochelle, France
🇫🇷CH Le Mans, Le Mans, France
🇫🇷Chru Brest, Brest, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.